Eledon Pharmaceuticals, Inc. (ELDN)


-0.09 (-3.27%)
Symbol ELDN
Price $2.66
Beta 1.911
Volume Avg. 0.03M
Market Cap 36.593M
Shares () -
52 Week Range 2.27-6.21
1y Target Est -
DCF Unlevered ELDN DCF ->
DCF Levered ELDN LDCF ->
ROE -18.07% Sell
ROA -18.70% Sell
Operating Margin -
Debt / Equity 3.57% Neutral
P/E -
P/B 0.25 Neutral


Consensus EPS

Upgrades & Downgrades

Latest ELDN news

NASDAQ Capital Market

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.